Verquvo Tablet, Film Coated
Product Images NDC 0006-5028

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Verquvo (NDC 0006-5028). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Merck Sharp & Dohme Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Verquvo 01)

Chemical structure of vericiguat, the active ingredient in VERQUVO, a prescription oral film-coated tablet available in strengths of 2.5 mg, 5 mg, and 10 mg from Merck Sharp & Dohme LLC.*

FDA Label Image

Figure 1 (Verquvo 02)

A forest plot chart depicting pharmacokinetic changes in Vericiguat (VERQUVO) related to patient characteristics (age, sex, weight, race, ethnicity, and baseline NT-proBNP quartile). It shows point estimates and 90% confidence intervals for AUC and Cmax after single and multiple dose administrations, with reference comparisons.*

FDA Label Image

Figure 2 (Verquvo 03)

A Kaplan-Meier curve comparing the cumulative incidence rate over time in months since randomization between VERQUVO and placebo groups. The graph shows two lines representing VERQUVO and placebo, with VERQUVO having a slightly lower incidence rate. Below the graph is a table showing the number of subjects at risk in each group at various time points up to 36 months.*

FDA Label Image

Figure 3 (Verquvo 04)

A forest plot chart comparing hazard ratios with 95% confidence intervals across various subgroups for vericiguat versus placebo. The chart includes population percentages, number of subjects treated with vericiguat and placebo, and evaluates factors such as gender, age groups, race, geographic region, race in North America, index event, baseline eGFR, NYHA class, use of sacubitril/valsartan, NT-proBNP levels, and ejection fraction groups. The plot visually indicates the favorability of vericiguat compared to placebo across these subgroups.*

FDA Label Image

Principal Display Panel (2.5 mg Bottle Label)

Label for Verquvo (vericiguat) tablets, 2.5 mg strength. The label shows the product name, dosage strength, and a depiction of a single round, white tablet embossed with '2.5'. It includes storage instructions and states the package contains 30 tablets. The labeler is Merck Sharp & Dohme LLC, with manufacturing information for facilities in the USA and Germany.*

FDA Label Image

Principal Display Panel (5 mg Bottle Label)

Label for Verquvo (vericiguat) tablets, 5 mg strength, film-coated oral tablets by Merck Sharp & Dohme LLC. The label shows the product name, strength, and a single round, reddish-brown tablet imprinted with '5'. It states the package contains 30 tablets and includes storage instructions and manufacturer information.*

FDA Label Image

Principal Display Panel (10 mg Bottle Label)

Label for Verquvo (vericiguat) tablets with a strength of 10 mg. The label shows a single film-coated tablet imprinted with '10'. It is a prescription oral tablet supplied by Merck Sharp & Dohme LLC and contains 30 tablets per package. Storage instructions and manufacturing details including locations in the USA and Germany are also displayed.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.